Skip to main content
PMCB logo
PMCB
(NASDAQ)
PharmaCyte Biotech, Inc.
$0.73-- (--)
Loading... - Market loading

PharmaCyte Biotech (PMCB) Income Statement

Revenue, expenses, profit margins, and earnings with annual and quarterly data.

PharmaCyte Biotech Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
PharmaCyte Biotech, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period EndingApr 2025Apr 2024Apr 2023Apr 2022Apr 2021Apr 2020Apr 2019Apr 2018Apr 2017
Revenue & Gross Profit
Revenue0.000.000.000.000.000.000.000.000.00
Cost of Revenue0.000.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.000.00
Operating Expenses
Research & Development0.440.410.470.690.920.300.462.001.18
Selling, General & Administrative3.946.115.993.702.713.533.644.983.26
Operating Expenses4.386.526.464.393.623.834.106.984.44
Operating Income-4.38-6.52-6.46-4.39-3.62-3.83-4.10-6.98-4.44
Other Income/Expense
Interest Income1.423.401.940.160.000.000.000.000.00
Interest Expense0.000.000.000.000.000.000.000.000.00
Other Income/Expense35.033.452.140.150.070.000.030.150.00
Income
Income Before Tax30.660.33-4.32-4.24-3.55-3.83-4.07-6.83-4.44
Income Tax Expense0.000.000.000.000.000.00-0.030.000.00
Net Income30.660.33-4.32-4.24-3.55-3.83-4.07-6.83-4.44
Net Income - Continuous Operations30.660.33-4.32-4.24-3.55-3.83-4.07-6.83-4.44
Net Income - Discontinued Operations0.000.000.000.000.000.000.000.000.00
EBITDA30.66-6.52-4.32-4.39-3.550.000.000.00-4.44
EBIT-4.38-6.52-6.46-4.39-3.620.000.000.000.00
Depreciation & Amortization0.006.526.460.000.003.834.106.984.44
Earnings Per Share
Basic EPS3.00-2.00--8.00-2.00-4.00-6.00-11.00-8.00
Diluted EPS3.00-2.00-1.00-8.00-2.00-4.00-6.00-11.00-8.00
Basic Shares Outstanding7.339.5819.490.521.450.900.730.650.56
Diluted Shares Outstanding7.339.585.180.521.450.900.730.650.56

These financial metrics are calculated using income statement data. Learn how each metric works and screen stocks by them.